Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 12/20 | 0.50 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.50 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | HTR2B | P41595 | 2/20 | 0.48 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.47 |
| ▸ | HRH2 | P25021 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | GPR4 | P46093 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3195004 | 0.91 | ALDH1A1 (0.50) | DRD3TLR9TLR7DRD2ALDH1A1 | |
| SCHEMBL21712258 | 0.85 | RXFP1 (0.51) | DRD3DRD2KCNA5RXFP1GPR4 | |
| SCHEMBL19479118 | 0.84 | DRD3 (0.70) | DRD3DRD2ALDH1A1KCNA5HRH2 | |
| SCHEMBL31268813 | 0.79 | DRD3 (0.53) | DRD3DRD2ALDH1A1GPR4EPHX2 | |
| SCHEMBL21724503 | 0.79 | RXFP1 (0.51) | DRD3DRD2ALDH1A1HTR2BRXFP1 | |
| SCHEMBL30943587 | 0.79 | DRD2 (0.48) | DRD3DRD2RXFP1GPR4 | |
| SCHEMBL3165435 | 0.78 | PDE4B (0.54) | ALDH1A1EPHX2 | |
| SCHEMBL18135536 | 0.78 | KCNA5 (0.64) | DRD3DRD2ALDH1A1KCNA5EPHX2 | |
| SCHEMBL31583944 | 0.78 | TLR9 (0.52) | TLR9TLR7ALDH1A1HRH2EPHX2 | |
| SCHEMBL3314377 | 0.78 | DRD3 (0.52) | DRD3DRD2ALDH1A1HRH2GPR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666866-B2 | Antithrombotic diamides | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | disclosed |
| EP-1819693-B1 | ANTITHROMBOTIC DIAMIDES | LILLY CO ELI (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20090062271-A1 | Antithrombotic Diamides | ELI LILLY AND COMPANY (US) | 2009-03-05 | — | — | US | disclosed |
| EP-1819693-A1 | ANTITHROMBOTIC DIAMIDES | ELI LILLY AND COMPANY (US) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006057868-A1 | ANTITHROMBOTIC DIAMIDES | ELI LILLY AND COMPANY (US) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062271-A1 | Antithrombotic Diamides | TFPI, SERPINC1, TFPI2 | DRD3 3262/4885TLR9 4709/4885TLR7 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.